Logo image of CGTX

COGNITION THERAPEUTICS INC (CGTX) Stock Fundamental Analysis

NASDAQ:CGTX - Nasdaq - US19243B1026 - Common Stock - Currency: USD

0.711  -0.01 (-0.7%)

After market: 0.7193 +0.01 (+1.17%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CGTX. CGTX was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of CGTX is average, but there are quite some concerns on its profitability. CGTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CGTX had negative earnings in the past year.
CGTX had a negative operating cash flow in the past year.
CGTX had negative earnings in each of the past 5 years.
CGTX had a negative operating cash flow in each of the past 5 years.
CGTX Yearly Net Income VS EBIT VS OCF VS FCFCGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -141.70%, CGTX is doing worse than 82.38% of the companies in the same industry.
CGTX has a worse Return On Equity (-271.39%) than 73.58% of its industry peers.
Industry RankSector Rank
ROA -141.7%
ROE -271.39%
ROIC N/A
ROA(3y)-76.04%
ROA(5y)-85.03%
ROE(3y)-113.24%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGTX Yearly ROA, ROE, ROICCGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

CGTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGTX Yearly Profit, Operating, Gross MarginsCGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for CGTX has been increased compared to 1 year ago.
The number of shares outstanding for CGTX has been increased compared to 5 years ago.
There is no outstanding debt for CGTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGTX Yearly Shares OutstandingCGTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CGTX Yearly Total Debt VS Total AssetsCGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

CGTX has an Altman-Z score of -15.49. This is a bad value and indicates that CGTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -15.49, CGTX is not doing good in the industry: 76.68% of the companies in the same industry are doing better.
There is no outstanding debt for CGTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.49
ROIC/WACCN/A
WACCN/A
CGTX Yearly LT Debt VS Equity VS FCFCGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

CGTX has a Current Ratio of 2.09. This indicates that CGTX is financially healthy and has no problem in meeting its short term obligations.
CGTX's Current ratio of 2.09 is in line compared to the rest of the industry. CGTX outperforms 40.41% of its industry peers.
CGTX has a Quick Ratio of 2.09. This indicates that CGTX is financially healthy and has no problem in meeting its short term obligations.
CGTX has a Quick ratio (2.09) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 2.09
CGTX Yearly Current Assets VS Current LiabilitesCGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.57% over the past year.
EPS 1Y (TTM)19.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CGTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.63% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.93%
EPS Next 2Y29.3%
EPS Next 3Y19.24%
EPS Next 5Y12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGTX Yearly Revenue VS EstimatesCGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M 400M
CGTX Yearly EPS VS EstimatesCGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGTX Price Earnings VS Forward Price EarningsCGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGTX Per share dataCGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as CGTX's earnings are expected to grow with 19.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.3%
EPS Next 3Y19.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COGNITION THERAPEUTICS INC

NASDAQ:CGTX (8/6/2025, 8:14:27 PM)

After market: 0.7193 +0.01 (+1.17%)

0.711

-0.01 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners18.77%
Inst Owner Change-0.41%
Ins Owners0.59%
Ins Owner Change23.7%
Market Cap44.07M
Analysts82
Price Target3.32 (366.95%)
Short Float %12.06%
Short Ratio0.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.93%
Min EPS beat(2)-24.49%
Max EPS beat(2)-17.37%
EPS beat(4)1
Avg EPS beat(4)-6.41%
Min EPS beat(4)-24.49%
Max EPS beat(4)25.17%
EPS beat(8)4
Avg EPS beat(8)1.92%
EPS beat(12)7
Avg EPS beat(12)5.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.75%
PT rev (3m)-39.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.46%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 3.59
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -141.7%
ROE -271.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.04%
ROA(5y)-85.03%
ROE(3y)-113.24%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 2.09
Altman-Z -15.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)90.78%
Cap/Depr(5y)63.13%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.15%
EPS Next Y51.93%
EPS Next 2Y29.3%
EPS Next 3Y19.24%
EPS Next 5Y12.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.45%
OCF growth 3YN/A
OCF growth 5YN/A